Natalie Silver, M.D.

Natalie L Silver, M.D., M.S.

(352) 273-5199

Request an Appointment


  • Silver N, Weber R. Chapter 12. Surgery for Malignant Submandibular Gland Neoplsams. In Eisele and Bradley (ed.), Advances of Oto-Rhino-Laryngology. Karger. Undergoing Revisions, Anticipated Publication 2016.
  • Tanaka N, Patel A, Wang J , Frederick M, Zhao M, Fitzgerald A, Xie T, Silver N, Caulin C, Zhou G, Skinner H , Johnson F, Myers J, Osman A. Wee-1 kinase inhibition sensitizes high risk HPV+ HNSCC to apoptosis through downregulation of MCl-1 and XIAP antiapoptotic proteins. Clinical Cancer Research, [Epub Ahead of Print] June 2015.
  • Silver N, Arnold S, Gleason J, Kudrimoti M, Brill Y, Van Metre E, Valentino J. p16INK4a Status and Response to Induction Low Dose Fractionated Radiation in Head and Neck Cancer. Annals of Otology Rhinology and Laryngology, [Epub Ahead of Print] May 2015.
  • Silver N, Sokoya F, Brill Y, Gal TJ. Laryngeal Blastomycosis. ENT Journal, Laryngology Clinics. Accepted 2014.
  • Silver N, TJ Gal. Endoscopic CO2 Laser Management of Chemoradiation Related Cricopharyngeal Stenosis. Annals of Otology Rhinology and Laryngology. 2014;123(4):252-6.
  • Gal TJ, Silver N. Chapter 116. Transoral Laser Resection of the Larynx. In Kountakis (ed.), Encyclopedia of Otolaryngology, Head and Neck Surgery. Springer-Verlag Berlin Heidelberg, 2013.
  • Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011;121(9):2026-33.
  • Ju JH, Maeng JS, Zemedkun M, Ahronovitz N (maiden name), Mack JW, Ferretti JA, Gelmann EP, Gruschus JM. Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor. Journal of Molecular Biology. 2006;360:989-99.
  • Gelmann EP, Steadman DJ, Ma J, Ahronovitz N (maiden name), Voeller HJ, Swope S, Abbaszadegan M, Brown KM, Strand K, Hayes RB, Stampfer MJ. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Research. 2002;62:2654-9.

Research Interests

  • Molecular therapeutics used to imrpove the outcome of head and neck squamous cell carcinoma patients who harbor deleterious TP53 mutations.
  • Expression of soluble vascular endothelial growth factor (VEGF) receptor-2 in head and neck cancer patients.
  • Epidermal growth factor receptor and downstream molecular signaling proteins in head and neck squamous cell carcinoma and salivary gland tumor cell lines.